Author

G. P. Kim

Observed institutions: Genentech, North Central Cancer Treatment Group, Sanofi (United States)

OpenAlex ID: A5043551111

NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma

2006 · G. P. Kim, A. Oberg, et al. · Journal of Clinical Oncology · 18

Phase I trial of everolimus and gemcitabine for patients with solid tumors refractory to standard therapy and for a cohort of patients with cholangiocarcinoma/gallbladder cancer.

2010 · B. A. Costello, Y. Qi, et al. · Journal of Clinical Oncology · 3

Phase II trial of ixabepilone (IXA) plus cetuximab (C) as first-line therapy for advanced pancreatic carcinoma (PC).

2010 · C. S. Rocha Lima, E. H. Lin, et al. · Journal of Clinical Oncology · 3

Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC).

2010 · G. P. Kim, S. Marsoni, et al. · Journal of Clinical Oncology · 2

Gemcitabine and docetaxel in patients with measurable unresectable or metastatic hepatocellular carcinoma (HCC), a North Central Cancer Treatment Group (NCCTG) phase II trial

2004 · G. P. Kim, S. R. Alberts, et al. · Journal of Clinical Oncology · 2

Genome-wide interaction study of gemcitabine treatment and genotype on survival in pancreatic cancer.

2011 · R. R. McWilliams, W. R. Bamlet, et al. · Journal of Clinical Oncology · 1

Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer Steven R. AlbertsTiffany M. YuRobert J. BehrensLindsay A. Renfro • Geetika SrivastavaGamini S. SooriShaker R. DakhilRex B. Mowat • John P. KueblerGeorge P. KimMiroslaw A. MazurczakJohn Hornberger

2014 · Robert J. Behrens, Gamini S. Soori, et al.

Works count: 7

Citation count: 29

H-index: 3

I10-index: 1